Aripiprazole Articles
Bristol-Myers Squibb issues profit warning for 2002
15 April 2002
Bristol-Myers Squibb slumps as Vanlev data disappoints
25 March 2002
Files aripiprazole in EU
7 January 2002
B-MS predicts EPS decline in 2002
7 January 2002
Files aripiprazole in EU
17 December 2001
B-MS predicts EPS decline in 2002
17 December 2001
Bristol-Myers Squibb highlights five key products at R&D day
15 November 2001
B-MS and Otsuka submit aripiprazole
8 November 2001
B-MS to file NDA for Abilitat in 4th quarter
27 April 2001
B-MS focuses on intense growth and reveals product pipeline
2 October 2000
B-MS reveals Ph III aripiprazole data
17 May 2000
B-MS, Otsuka link up on new antipsychotic
22 September 1999
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
